Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke

INTRODUCTION: Stroke is a common cause of epilepsy that may be mediated via glutamate dysregulation. There is currently no evidence to support the use of antiseizure medications as primary prevention against poststroke epilepsy. Perampanel has a unique antiglutamatergic mechanism of action and may h...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open
Main Authors: Nicolo, John-Paul, Chen, Zhibin, Moffat, Bradford, Wright, David K, Sinclair, Benjamin, Glarin, Rebecca, Neal, Andrew, Thijs, Vincent, Seneviratne, Udaya, Yan, Bernard, Cloud, Geoffrey, O'Brien, Terence J, Kwan, Patrick
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2021
Assuntos:
Neurology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8112439/
https://ncbi.nlm.nih.gov/pubmed/33972334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-043488
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados